Abstract
Objective To explore the clinical efficacy of tirofiban combined with ticagrelor and aspirin in acute myocardial infarction treatment by percutaneous coronary intervention and its effect on patients' cardiac function. Methods We selected 102 patients with acute myocardial infarction who came to The First Hospital of LanZhou University for treatment from July 2018 to May 2021. On the basis of conventional treatment, patients were separated into a joint group (tirofiban combined with ticagrelor and aspirin) comprising 55 cases and a control group (conventional ticagrelor and aspirin dual treatment) involving 47 cases. Blood flow classification of the two groups of patients was immediately recorded and compared after the myocardial infarction thrombolysis test (TIMI). Left ventricular function-related indicators, platelet-related parameters, neutrophil/lymphocyte ratio (NLR), red blood cell distribution width (RDW), and platelet/lymphocyte ratio (PLR) before treatment and 7 days after PCI were evaluated and compared between the groups before treatment and 3 months after treatment. ELISA was utilized to detect the serum levels of inflammatory factors, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and hypersensitive C-reactive protein (hs-CRP) before and after treatment. Incidence of major adverse cardiovascular events (MACEs) and adverse reaction incidence was put into comparison between the two groups in the course of the 3-month follow-up period. Compared with the control group, the joint group accounted for more patients with TIMI blood flow classification level 3 (P < 0.05) and showed more drastic improvement on the left ventricular function, platelet-related parameters, and serum inflammatory factors (P < 0.05). Moreover, patients of the joint group suffered less fluctuation from RDW, NLR, and PLR (P < 0.05), and their incidence of MACE was drastically lower in contrast with the control group (P < 0.05). No notable changes were presented in terms of incidence of adverse reaction (P > 0.05). For patients who suffered from acute myocardial infarction and treated with percutaneous coronary intervention, the application of tirofiban combined with ticagrelor and aspirin could effectively reduce the incidence of no reflow or slow blood flow, improve myocardial perfusion function, and have marked curative effects. It is worthy of clinical promotion and application.
Highlights
Acute myocardial infarction (AMI) is a cardiovascular disease with a high fatality rate caused by persistent myocardial ischemia and hypoxia, which can cause myocardial tissue necrosis and myocardial inflammation [1, 2]
Information has existed currently about the use of tirofiban combined with ticagrelor and aspirin in the treatment of acute myocardial infarction in Percutaneous coronary intervention (PCI)
On the basis of that, this study proposes the use of tirofiban combined with ticagrelor and aspirin in patients with acute myocardial infarction undergoing PCI treatment, thereby providing more reference treatment options for antiplatelet therapy in patients with acute myocardial infarction. e results of this study showed that tirofiban combined with ticagrelor and aspirin could bring more benefits to patients with acute myocardial infarction undergoing PCI treatment
Summary
Acute myocardial infarction (AMI) is a cardiovascular disease with a high fatality rate caused by persistent myocardial ischemia and hypoxia, which can cause myocardial tissue necrosis and myocardial inflammation [1, 2]. Percutaneous coronary intervention (PCI), an important method for infarction-related vascular reperfusion in patients with AMI in recent years, is currently widely regarded as one of the most efficient methods for AMI treatment, which can effectively relieve the obstruction and restore myocardial perfusion, thereby reducing the area of Journal of Healthcare Engineering myocardial tissue necrosis and significantly improving the prognosis of patients to reduce the fatality rate [4, 5]. As one of the conventional platelet GPIIb/III, a receptor antagonist, tirofiban has been found in the past to show good clinical effects in patients diagnosed with ST-segment elevation myocardial infarction (STEMI) undergoing emergency PCI, which can improve coronary blood flow, increase myocardial reperfusion, and help improve the efficacy [10]. Past studies have shown that patients with heart failure would have significant LVEDD, LVESD increase, and LVEF decrease. erefore, it is used as an index to evaluate a patient’s cardiac function in this study
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
